Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exparel for Postsurgical Analgesia in Minimally Invasive Supracervical Hysterectomy
NCT03769714Phase 4Completed
- Sponsor
- Maimonides Medical Center
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupivacaine in Persistent postsurgical pain (PPSP) (2 arms), sponsored by Maimonides Medical Center. Primary endpoints: Pain at 12 Hours and Pain at 48 Hours. Started Oct 2018; status: completed.
02
Drugs
bupivacaine
03
Conditions
Persistent postsurgical pain (PPSP)
Beyond the preview
Go deeper on NCT03769714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769714.